創薬流通市場「薬市楽座」

安土桃山時代に自由取引市場として発展した「楽市楽座」にあやかり、創薬シーズ・技術のマーケットプラットフォームを創薬流通市場、「薬市楽座」と名付けました。このマーケットが楽市楽座のように発展することを願っています。

創薬流通市場である薬市楽座では、弊社がお預かりしている創薬シーズ・技術の情報をリストアップしています。ご興味に応じて検索していただくことが可能です。また、リストのダウンロードも行っていただけます。ご興味のあるものがあれば、お問い合わせボタンをクリックしていただき、弊社へのコンタクトをお願いいたします。追加情報を開示させていただきます。

なお、2019年6月27日より、日本語ページにおける、創薬シーズ、創薬技術の各リスト表記が英語に変更になりました。ダウンロード用のPDF、エクセルファイルは英語ページよりダウンロードできる資料と同一ですので、予めご了承下さいませ。

創薬シーズ・創薬技術一覧(PDF) 疾患領域別 創薬シーズ一覧(PDF) 創薬シーズ・創薬技術一覧(Excel)

絞り込み検索

掲載日 シーズ番号 作用機序 適応症 投与経路 モダリティ 開発ステージ 備考
18/07/26 GEM032 Calcium release-activated calcium channel inhibitor Respiratory & Immuno-inflammatory diseases Oral Small molecule
Phase 1 - Preclinical study demonstrated the therapeutic potential in respiratory diseases causally associated with allergic inflamation.
- Phase 1 SAD/MAD study were completed.
問合せ
18/07/26 GEM031 Store-Operated Calcium Entry (SOCE) Inhibitor Lymphomas & Solid cancer Oral Small molecule
Phase 1 - Demonstrated preclinical activity in a broad range of cancers.
- Phase 1 dose-escalation study in patients with relapsed or refractory lymphomas is ongoing.
問合せ
18/07/26 GEM030 PI3K δ/γ dual inhibitor Hematological malignancies, T cell lymphoma, Hodgkin lymphoma Oral Small molecule
Phase 2 - Highly specific dual PI3K δ/γ inhibitor with nano‐molar inhibitory potency
- Single-agent and combination with immune checkpoint inhibitor programs
- Inhibits primary patient leukemic/lymphoma cells
- Dose escalation study demonstrated an acceptable safety and tolerability with promising clinical activity
問合せ
18/07/20 GEM029 A cancer stem cell-associated transcription factor inhibitor Malignant gliomas including glioblastoma (GBM) Oral Small molecule
Phase 1 ready -Directly kills the cancer stem cells.
-Significantly improves survival in orthotopic GBM PDX models.
-Inhibits tumor growth in a mouse implanted with GBM cells and the growth inhibition is augmented by combination with temozolomide/radiation.
-No significant toxicities are identified at therapeutic doses.
問合せ
18/07/09 GEM028 miRNA targeting refractory colon cancer with mutated K-ras and refractory pancreatic cancer Pancreatic cancer, Colon cancer i.v. Nucleic acid
Preclinical The miRNA regulates K-ras, Bcl2, survivin, and NF-kB and demonstrate excellent antitumor effect in vitro and in vivo. 問合せ
18/07/09 GEM027 miRNA targeting refractory colon cancer with mutated K-ras Colon cancer i.v. Nucleic acid
Preclinical The miRNA regulates EGFR signaling pathway by directly inhibiting of both KRAS and AKT1 and demonstrate excellent antitumor effect in vitro and in vivo. 問合せ
18/07/09 GEM026 siRNA suppressing the expression of novel cancer stem cell gene "Gene A" Cancer i.v. Nucleic acid
Preclinical -Novel cancer stem cell gene "Gene A", which was discovered by single cell analysis of cancer stem cell, shows character as follows.
1.Superior cancer stem cell diagnostic marker than known cancer stem cell marker CD44v9
2.SiRNA targeting Gene A demonstrate excellent antitumor effect with currnet medicines.
問合せ
18/07/09 GEM025 miRNA suppressing the expression of a protein characteristic of pancreatic cancer stem cells pancreatic cancer i.v. Nucleic acid
Preclinical Excellent antitumor effect was demonstrated in uniquely established pancreatic cancer stem cell model in vitro and in vivo. 問合せ
18/07/05 GEM023 Synthetic miniprotein for influenza virus Infuenza Inhaled Protein
Preclinical Computationally designed miniprotein with demonstrated pre and post-exposure efficacy against the disease.
-Neutralizes multiple variants like H1N1 and H5N1 better than today’s standard of care while keeping immunogenicity low enough to allow chronic treatments.

Route : Inhaled
問合せ
18/07/05 GEM021 Opioid and non-opioid analgesics with respiratory stimulant Pain Oral Small molecule
Preclinical (close to IND) -Combination of generic opioid/non-opioid analgesics with a generic respiratory stimulant using a regulatory approach known as the 505(b)2 submission.
-First drug introduction therapeutically equivalent to Vicodin® that prevents overdose death, deters abuse and prevents addiction.
-Low cost of goods.
問合せ